News

The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from preclinical to clinical phase of drug development.

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to needed resources.

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated for treatment of AMD.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.

Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.

The device recently received 510(k) clearance from the US Food and Drug Administration.

The main outcomes were the measurements of the visual acuity and visual field defects.

Investigators examined the connection between amblyopia, components of the metabolic syndrome and individual cardiometabolic diseases.

Among these eyes, 18.9% of eyes developed nAMD within 36 months.

Zhaoke Ophthalmology Limited is responsible for developing and obtaining regulatory approval for NVK-002 in Greater China, South Korea, and the Southeast Asian territories.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The program will deliver a range of high-quality access and affordability services for retina specialists.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The companies will work together by using the codon-optimized BBS1 AAV9 vector to minimize the vision loss caused by the genetic defects in the BBS1 gene.

The company states LYNX is the world’s first and only pattern scanning laser indirect ophthalmoscope and is battery-powered to provide surgeons with an untethered laser solution.

The investigators found that the premature births to be associated with vascular changes on ocular coherence tomography-angiography.

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.

The “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments and suprachoroidal hemorrhages.

Funds from the Inasmuch Foundation and The Samuel Roberts Noble Foundation will support the purchase of equipment, including computerized eye simulators, a laser injector, and a device for measuring the electrical resistance of cells.

The meetings support the company’s submission for its bioengineered corneal implants to eliminate corneal blindness.

Chen and colleagues conducted a longitudinal study that included patients with high myopia who were followed for 10 years. Detailed ophthalmic examinations were conducted at the baseline and follow-up visits that included measurements of the BCVA and visual fields in 568 eyes of 284 patients.

The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.